Unleashing the power of the immune system to fight cancer | Oncolytics...
Oncolytics Biotech. Oncolytics is developing pelareorep, a unique immunotherapy with broad antitumor potential.
Read Oncolyticsbiotech.com news digest here: view the latest Oncolytics Biotech articles and content updates right away or get to their most visited pages. Oncolyticsbiotech.com belongs to a large group of moderately popular websites, with around 4.9K visitors from all over the world monthly. It seems that Oncolytics Biotech content is notably popular in Canada, as 77.4% of all users (3.8K visits per month) come from this country. We haven’t detected security issues or inappropriate content on Oncolyticsbiotech.com and thus you can safely use it. Oncolyticsbiotech.com is hosted with Vultr Holdings, LLC (United States) and its basic language is English.
Content verdict: Safe
Website availability: Live
Language: English
Last check:
-
165
Visitors daily -
494
Pageviews daily -
4
Google PR -
528 521
Alexa rank
Best pages on Oncolyticsbiotech.com
-
Unleashing the power of the immune system to fight cancer | Oncolytics Biotech
Oncolytics is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential across cancer types
-
REOLYSIN® – Oncolytics Biotech Inc.
Sep 1, 2016 .@AmericanCancer estimates ~224,390 Americans will be diagnosed with #lungcancer in 2016 and ~158,080 of them will die from it. Sep 1, 2016 "There...
-
Clinical Trials | Reolysin® | Oncolytics Biotech Inc.
Oncolytics Biotech Inc. is conducting clinical trials in multiple indications with the objective of developing REOLYSIN® as a human cancer therapeutic.
Domain history
| Web host: | Vultr Holdings, LLC |
| Registrar: | Network Solutions, LLC |
| Registrant: | Oncolytics Biotech Inc. |
| Updated: | December 26, 2021 |
| Expires: | February 24, 2025 |
| Created: | February 24, 2000 |
Whois record
Safety scores
Trustworthiness
ExcellentChild safety
N/A
